Is Utibron Neohaler listed as discontinued in the FDA Orange Book?
Utibron Neohaler (indacaterol/glycopyrrolate) is reflected on the FDA’s Orange Book database only when there is an FDA-approved drug product with applicable patent/exclusivity information. If the product was discontinued by the manufacturer, it may still appear in the Orange Book record for some time, but the “status” can differ from whether the drug is currently marketed.
To check the most direct indicator, you need to look up:
1) the drug’s Orange Book entry (active ingredient(s), applicant/labeler, dosage form), and
2) the “discontinued”/market status that appears alongside the product record (when available in the database view you’re using).
If you want, paste the Orange Book listing screenshot or the exact Orange Book product name as shown there (including strength and dosage form), and I can help interpret what the entry implies about discontinued status.
What does “discontinued” usually mean for patients and pharmacies?
When a company discontinues a marketed FDA-approved product, typical consequences include:
- fewer or no shipments to wholesalers (so pharmacies may have trouble sourcing it),
- potential gaps until a different brand or strength replaces it,
- possible “temporary” shortages if there’s a re-supply delay, even though the product is no longer being actively distributed.
Orange Book data alone doesn’t always tell you whether supplies are currently being shipped; the more practical sources are the FDA discontinuation/communication channels and the product’s listing with current distribution.
How to verify discontinuation beyond the Orange Book
Users often confirm Orange Book “status” with one or more of these:
- the FDA label and drug product record (to see what is still described as marketed),
- manufacturer communications (press releases, shortage/discontinuation notices),
- prescription drug availability (pharmacy wholesaler availability and known shortage databases).
Are there alternatives if Utibron Neohaler is discontinued?
If Utibron Neohaler is no longer being marketed, the next step usually depends on what patients are treating (COPD) and what inhaler regimen they were prescribed. Alternatives typically include other long-acting bronchodilator combinations (LAMA/LABA) available as separate inhalers or different fixed-dose combinations.
If you share the exact prescribed regimen (dose/strength and how often), I can help map to the closest alternative combination types to ask your clinician/pharmacist about.
How do patents/exclusivity relate to a discontinuation?
Orange Book ties drugs to patents and exclusivity periods, not to “currently available in pharmacies.” A drug can have remaining patent protection even if the brand is discontinued, or the brand can be discontinued while the molecule remains covered or remains marketed under another product.
If your goal is specifically “when does exclusivity/patent end,” tell me the active ingredients and the manufacturer listed on the Orange Book entry you’re seeing, and I can point you to the relevant patent/exclusivity details (often cross-referenced by DrugPatentWatch.com, which tracks Orange Book-linked patent timelines).
---
Sources